RASopathies, such as cardio-facio-cutaneous (CFC) syndrome and Noonan syndrome, are rare developmental diseases caused by germline mutations that lead to overactivation of the RAS-MAPK pathway. Anastasaki et al. build on previous work to test whether fine-tuning doses of PD0325901, an inhibitor of this pathway that is in clinical use for cancer treatment, can minimise the developmental defects of RASopathies. Using zebrafish embryos, they show that continuous, low doses of PD0325901 during development prevents the detrimental effects of a CFC-associated mutation without inducing the side effects observed when inhibiting the pathway using higher doses of the drug. Thus, anti-cancer agents that target the RAS-MAPK pathway might hold promise for these devastating developmental diseases. Page 546
Fine-tuning candidate therapy for RASopathies
Fine-tuning candidate therapy for RASopathies. Dis Model Mech 1 July 2012; 5 (4): 413. doi:
Download citation file:
Advertisement
Cited by
Sex matters in preclinical research
DMM calls for improved inclusion, analysis and reporting of sex as a biological variable in preclinical animal modelling research. Read the full Editorial by Monica J. Justice.
Subject collection: Building advocacy into research
DMM’s new series - Building advocacy into research - features interviews, ‘The Patient’s Voice’, with patients and advocates for a range of disease types, with the aim of supporting the highest quality research for the benefit of all patients affected by disease.
Travelling Fellowships for early-career researchers
DMM and its sister journals offer Travelling Fellowships of up to £3,000 to graduate students and post-doctoral researchers wishing to make collaborative visits to other laboratories. Find out more about our Travelling Fellowships and read stories from previous grant recipients.
Read & Publish Open Access publishing: what authors say
We have had great feedback from authors who have benefitted from our Read & Publish agreement with their institution and have been able to publish Open Access with us without paying an APC. Read what they had to say.
The Forest of Biologists
Our Publisher Claire Moulton recently visited the two Woodland Trust UK sites where we are planting new native trees for published Research and Review papers and protecting ancient woodland on behalf of our peer reviewers.
Other journals from
The Company of Biologists